Medibank shares fall despite big 2030 transformation plans

Let's see what Medibank is planning for a big earnings boost.

| More on:
meal preparation of healthy food in a family kitchen

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Medibank Private plans to accelerate its transformation into a leading health company by expanding its role beyond insurance into the broader healthcare system.
  • The company aims to increase earnings from its health segment to $200 million by FY 2030 and grow its policyholder market share while focusing on wellbeing, primary care, community care, and insurance.
  • CEO David Koczkar emphasises transforming healthcare delivery from treatment to prevention and enhancing digital and personalised care to sustain health outcomes.

Medibank Private Ltd (ASX: MPL) shares are in the spotlight on Wednesday.

In morning trade, the health insurance giant's shares are down almost 1% to $4.86.

Medibank shares drop despite transformation plans

This morning, the private health insurer unveiled an ambitious plan to accelerate its transformation into a leading Australian health company.

Ahead of a "health immersion" event for investors today, it outlined how it plans to expand its role beyond health insurance and into the broader healthcare system.

Ambitious FY 2030 targets

Medibank has set out a series of long-term aspirations aimed at strengthening its business and driving shareholder value.

The company now aims to lift earnings from its Medibank Health segment to at least $200 million by FY 2030. This is up from $76.7 million in FY 2025.

It also aims to grow its policyholder market share each year in a disciplined way, targeting at least 26.8% by FY 2030.

A third target for 2030 is to double its health and wellbeing engagement, reaching around 10 million Australians by the end of the decade.

Commenting on the targets, Medibank's chief executive officer, David Koczkar, said:

Australia's healthcare system is one of the best in the world, but it is under pressure and urgently needs meaningful transformation to ensure we can keep up with the increasing needs in the community. It's time for the health system to shift from treatment to prevention, from hospital to community, from analogue to digital and from generic to personalised care. Investing in technology and connecting health is critical to accelerate this momentum. These four big shifts are essential to drive the health transition and to sustain the world leading health outcomes we all experience today.

Medibank has been driving the health transition. Over the last decade, we have invested more than $300 million to grow as a health company. We will remain focused on delivering for our customers and long-term value for our shareholders by accelerating our growth strategy, and today we have set out some very clear milestones alongside a new ambition.

Growth in four key segments

To achieve its goals, Medibank plans to focus on four major health areas. They are as follows:

  • Wellbeing – Expanding its Live Better rewards program, workplace health initiatives, and financial wellbeing offerings.
  • Primary care – Growing its general practice network and virtual healthcare services under its Amplar Health brand.
  • Community and acute care – Providing hospital-level care at home and expanding short-stay and rehabilitation services.
  • Health insurance – Continuing to improve value and choice for its 4.2 million policyholders.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Female scientist working in a laboratory.
Healthcare Shares

Telix shares in focus as the company meets guidance

More good news from the drug developer.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

What are the healthcare stocks where RBC Capital Markets thinks you can make money?

The top buys in the sector, listed.

Read more »

A sad looking scientist sitting and upset about a share price fall.
Healthcare Shares

Polynovo shares fall despite yesterday's upbeat update. Here's what investors are watching

Polynovo shares slide after a solid update as investors wait for clearer growth signals.

Read more »

Woman flexes muscles after donating blood.
Healthcare Shares

Check out this CSL share price forecast for 2026. It's hard to believe!

RBC Capital Markets thinks CSL is a bargain at current levels.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Good news out of China has this drug company's shares higher

A major new market will open up following this approval.

Read more »

woman in lab coat conducting testing.
Healthcare Shares

This rising ASX 200 stock isn't done yet – or is it?

Inching closer to FDA approval, the share price is falling. Analysts still see 21% to 106% upside.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Mesoblast just cleared a key FDA hurdle. So why are investors exiting?

Mesoblast shares slide to a 2-month low despite positive FDA feedback on its lead cell therapy product.

Read more »

Man leaps as he runs along the street.
Healthcare Shares

ASX 300 stock jumps 6% on strong half-year results and cash flow surge

Let's see how this medical device company performed during the first half.

Read more »